Given the particular role that has been ascribed to sclerostin at the level of the bone [27], the rather mild effects on the bone observed in our present study can be potentially explained by the significant increase in vascular-derived serum sclerostin levels and are compatible with the contribution of vascular sclerostin to the high incidence of low bone turnover in CKD patients. This evidence concerns the gene SOST and chronic kidney disease.